Clinical Trial Update: Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial updating epacadostat plus pembrolizumab in metastatic or unresectable gastroesophageal junction or gastric cancer (completed; results posted 2020-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer Ajcc V7
• Esophageal Carcinoma
• Gastric Adenocarcinoma
• Gastric Cancer Ajcc V7
• Gastric Carcinoma
• Gastroesophageal Junction Adenocarcinoma
• Unresectable Esophageal Carcinoma

Drugs mentioned

• Epacadostat (epacadostat)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: George Albert Fisher | Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2020-06-22